Lukas Ley
Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Lukas Ley appears in 20 tracked papers (2019–2026), most studied alongside LSD, MDMA and Psilocybin, across Healthy Volunteers, Anxiety Disorders and Medicinal Chemistry & Drug Development.
Most-cited paper: Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. (248 citations).
Frequent co-authors: Matthias Liechti, Friederike Holze and Patrick Vizeli.
Background & Research
Lukas Ley is a clinical researcher active in contemporary human psychedelic research, appearing as a co‑author on multiple randomized, double‑blind, placebo‑controlled studies that characterise acute psychopharmacological effects of classic and entactogenic psychedelics. His contributions span dose–response investigations of lysergic acid diethylamide (LSD), intravenous DMT administration studies, co‑administration work with MDMA and LSD, and head‑to‑head comparative acute trials of mescaline, LSD and psilocybin in healthy participants. Many of these studies emphasise rigorous experimental design, safety pharmacology and methodological considerations such as blinding and crossover protocols.
Key Impact
Notable for contributions to human experimental psychedelic pharmacology, including double-blind, placebo-controlled studies of LSD, DMT, MDMA co‑administration and comparative trials of classic psychedelics in healthy volunteers.
Collaboration Network
27 collaborators· click a node to visit their profile
Full network →